Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Blood (2023) 142 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2023-192022

Published: 2023

Journal Articles

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Elizabeth Stenger, Tami D. John, Deepak Chellapandian, Rikin Shah, Scott Gillespie, Yijin Xiang, Katie Liu, Monica Bhatia, Gregory M.T. Guilcher, Jennifer Jaroscak, Kimberly A. Kasow, Jennifer Krajewski, Alexander I. Ngwube, Hemalatha G. Rangarajan, John T. Horan, Lakshmanan Krishnamurti, Shalini Shenoy, Allistair Abraham

Blood (2023) 142 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2023-188514

Published: 2023

Journal Articles

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Blood (2023) 142 (Supplement 1): 4904.

https://doi.org/10.1182/blood-2023-182532

Published: 2023

Journal Articles

Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells

Shweta Bansil, Cecilia Motta, Rachel Dicioccio, Samuel O'Brien, Haili Lang, Michael Keller, Allistair Abraham, David Jacobsohn, Blachy J Davila Saldana, Amanda L. Olson, Elizabeth J Shpall, Indreshpal Kaur, Patrick J Hanley, Catherine M Bollard

Blood (2022) 140 (Supplement 1): 10239–10240.

https://doi.org/10.1182/blood-2022-167874

Published: 2022

Journal Articles

Percent Patient NK and T Cells at Day 28 Predict Graft Outcome after Haploidentical Hematopoietic Cell Transplant for Sickle Cell Disease

Mariah Jensen-Wachspress, Haili Lang, Gelina Sani, Deepali K Bhat, Emily Limerick, Xin Xu, Kenneth Fulton, Catherine M Bollard, Courtney D. Fitzhugh, Allistair Abraham

Blood (2022) 140 (Supplement 1): 7609–7610.

https://doi.org/10.1182/blood-2022-166878

Published: 2022

Journal Articles

Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study

Sobenna A George, Anirudh Veludhandi, Yijin Xiang, Elizabeth Stenger, Staci D. Arnold, Akanksha Mehta, David A Schirmer, Jessica B Spencer, Gregory M Guilcher, Monica Bhatia, Allistair Abraham, Veronica Gomez-Lobo, Lakshmanan Krishnamurti, Lillian R Meacham

Blood (2022) 140 (Supplement 1): 1391–1392.

https://doi.org/10.1182/blood-2022-168060

Published: 2022

Journal Articles

Disease Burden and Pre-Transplant Health-Related Quality of Life in Pediatric Sickle Cell Disease Patients Receiving Nonmyeloablative HLA-Identical Sibling Donor Transplantation

Jeremy Zack, Robert Sheppard Nickel, Allistair Abraham, Steven J. Hardy

Blood (2021) 138 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2021-153310

Published: 2021

Journal Articles

Nonmyeloablative HLA-Identical Sibling Donor Transplantation for Children and Young Adults with Sickle Cell Disease: Interim Results of the SUN Multicenter Phase II Trial

Robert Sheppard Nickel, KY Chiang, Steven J. Hardy, Hemalatha G Rangarajan, Sonali Chaudhury, Michael Kent, Monica Bhatia, Jeremy Zack, Vivitha Mani, Gregory M.T. Guilcher, Allistair Abraham

Blood (2021) 138 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2021-144454

Published: 2021

Journal Articles

HLA Typing Status of Hospitalized Pediatric Patients with Sickle Cell Disease: Impact of Socioeconomics and an Initiative to Offer Typing to All Patients with Siblings

Arrey-Takor Ayuk-Arrey, Isha Darbari, Allistair Abraham, Robert Sheppard Nickel

Blood (2021) 138 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2021-153807

Published: 2021

Journal Articles

Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)

Anirudh Veludhandi, Tami D John, Nitya Bakshi, Staci D. Arnold, Monica Bhatia, Peter A. Lane, Lillian Meacham, Kirshma Khemani, Sonali Chaudhury, Festus Olusola Olowoselu, Kimberly A. Kasow, Matthew Hsieh, Allistair Abraham, Gregory M.T. Guilcher, Lakshmanan Krishnamurti

Blood (2021) 138 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2021-152383

Published: 2021

Journal Articles

Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)

Staci D. Arnold, Nitya Bakshi, Zhao Chang, Diana Ross, Allistair Abraham, Monica Bhatia, Gregory M.T. Guilcher, Ann Haight, Matthew Hsieh, Kimberly A. Kasow, Peter A. Lane, Lillian Meacham, Festus Olusola Olowoselu, Lakshmanan Krishnamurti

Blood (2021) 138 (Supplement 1): 425.

https://doi.org/10.1182/blood-2021-154280

Published: 2021

Journal Articles

Adding Hydroxyurea to Chronic Transfusion for Sickle Cell Anemia Reduces Transfusion Burden: Final Results of the HAT Prospective Trial

Robert Sheppard Nickel, Stefanie Margulies, Brittany Frazer, Allistair Abraham, Naomi Luban, Jennifer Webb

Blood (2021) 138 (Supplement 1): 2036.

https://doi.org/10.1182/blood-2021-144453

Published: 2021

Journal Articles

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Niketa C. Shah, MD, Sweta Bhoopatiraju, Allistair Abraham, MD, Eric Jon Anderson, MD, Martin Andreansky, MD, Monica Bhatia, MD, Sonali Chaudhury, MD, Geoff D.E. Cuvelier, MD, Kamar Godder, MD MPH, Michael Grimley, MD, Gregory Hale, MD, Naynesh Kamani, David Jacobsohn, MD, Alexander I. Ngwube, MD, Jodi L. Skiles, MD, Lolie C. Yu, MD, Shalini Shenoy, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-142696

Published: 2020

Journal Articles

Pediatric Hematologist/Oncologists' Beliefs about Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Study

Emily Riehm Meier, MD MSHS, Allistair Abraham, MD, Alexander I. Ngwube, MD, Isaac Janson, PhD, Gregory M.T. Guilcher, MD, John T. Horan, MDMPH, Kimberly A. Kasow, DO

Blood (2019) 134 (Supplement_1): 2164.

https://doi.org/10.1182/blood-2019-130543

Published: 2019

Journal Articles

Effects of Combination Hydroxyurea and Chronic Red Blood Cell Transfusion Therapy on the Immune Parameters of Patients with Sickle Cell Disease

Mahogany Oldham, Gelina Sani, Stefanie Margulies, MS, Jennifer Webb, MD MSCE, Robert Sheppard Nickel, MDMSc, Allistair Abraham, MD

Blood (2019) 134 (Supplement_1): 4840.

https://doi.org/10.1182/blood-2019-126180

Published: 2019

Journal Articles

HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study

Robert Sheppard Nickel, MD MSc, John T. Horan, MD MPH, Allistair Abraham, MD, Muna Qayed, MD MSc, Ann Haight, MD, Naomi Luban, MD, Jeanne E. Hendrickson, MD

Blood (2018) 132 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2018-99-114116

Published: 2018

Journal Articles

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation

Courtney W. Johnson, MD MSc, Suvankar Majumdar, MBCHB, Andrew D. Campbell, MD, Suresh Magge, MD, Deepika S. Darbari, MD, Jennifer Webb, MD, Yaser A. Diab, MBBS, Robert Sheppard Nickel, MDMSc, Barbara Speller-Brown, DNP, CPNP-BC, Jessica Carpenter, MD, Allistair Abraham, MD

Blood (2018) 132 (Supplement 1): 1098.

https://doi.org/10.1182/blood-2018-99-118693

Published: 2018

Journal Articles

Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)

Allistair Abraham, MD, Elizabeth Stenger, MD, Curtis D Travers, MPH, Robert Nickel, MDMSc, Hemalatha G. Rangarajan, MD, Jennifer Krajewski, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Troy C. Quigg, DO, Alexander I. Ngwube, MD, Jennifer Jaroscak, MD, Gregory M Guilcher, MDBSc,FRCPC, Shalini Shenoy, MD, John T Horan, MD

Blood (2017) 130 (Supplement 1): 3535.

https://doi.org/10.1182/blood.V130.Suppl_1.3535.3535

Published: 2017

Journal Articles

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Elizabeth Stenger, MD, Allistair Abraham, MD, Curtis D Travers, MPH, Hemalatha G. Rangarajan, MD, Diane Hsu, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Michael J. Eckrich, MD MPH, Alexander I. Ngwube, MD, Julie Kanter, MD, Gregory M Guilcher, MDBSc,FRCPC, John T. Horan, MDMPH, Lakshmanan Krishnamurti, MD, Shalini Shenoy, MD

Blood (2017) 130 (Supplement 1): 3271.

https://doi.org/10.1182/blood.V130.Suppl_1.3271.3271

Published: 2017

Journal Articles

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Andrew C. Harris, MD, Jaap Jan Boelens, MDPhD, Kwang Woo Ahn, PhD, Mingwei Fei, MS, Allistair Abraham, MD, Andrew Artz, MD, Christopher C. Dvorak, MD, Haydar Frangoul, MD, Cesar O Freytes, MD, Robert Peter Gale, MD PhD, Sanghee Hong, MD, Hillard M. Lazarus, MD, Shin Mineishi, MD, Taiga Nishihori, MD, Tracey O'Brien, MD, Kirsten M. Williams, MD, Marcelo C. Pasquini, MD, John E Levine, MD MS

Blood (2016) 128 (22): 664.

https://doi.org/10.1182/blood.V128.22.664.664

Published: 2016

NARROW

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells

Percent Patient NK and T Cells at Day 28 Predict Graft Outcome after Haploidentical Hematopoietic Cell Transplant for Sickle Cell Disease

Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study

Disease Burden and Pre-Transplant Health-Related Quality of Life in Pediatric Sickle Cell Disease Patients Receiving Nonmyeloablative HLA-Identical Sibling Donor Transplantation

Nonmyeloablative HLA-Identical Sibling Donor Transplantation for Children and Young Adults with Sickle Cell Disease: Interim Results of the SUN Multicenter Phase II Trial

HLA Typing Status of Hospitalized Pediatric Patients with Sickle Cell Disease: Impact of Socioeconomics and an Initiative to Offer Typing to All Patients with Siblings

Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)

Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)

Adding Hydroxyurea to Chronic Transfusion for Sickle Cell Anemia Reduces Transfusion Burden: Final Results of the HAT Prospective Trial

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Pediatric Hematologist/Oncologists' Beliefs about Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Study

Effects of Combination Hydroxyurea and Chronic Red Blood Cell Transfusion Therapy on the Immune Parameters of Patients with Sickle Cell Disease

HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation

Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only